Back to News
Market Impact: 0.35
BMY Up 3% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
Source: zacks.com
Corporate EarningsAnalyst EstimatesHealthcare & BiotechCompany Fundamentals
Bristol Myers Squibb gained 3% after beating third-quarter estimates. The company’s Growth Portfolio and promising pipeline supported revenue prospects despite generic competition.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
Ticker Sentiment
BMY0.70
More News
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Palantir reports booming U.S. commercial revenue growth, topping government for first time
- Anthropic releases amended IPO prospectus with third-quarter financials
- Coinbase has been battered over the past month. Morgan Stanley says steer clear
- The AI boom is facing another supply crunch. This time it’s the amount of capital available to feed Silicon Valley’s endless need for cash
- Anthropic to Spend $895 Billion in the Years Ahead